רווח למניה בשנים עשר החודשים האחרונים: Fate Therapeutics Inc (FATE)

Fate Therapeutics, Inc. (FATE) is pursuing expansion in immunotherapy through clinical trials, developing affordable treatment methods based on its iPSC platform. An ecosystem of programmable drugs solidifies its role as a biotech intellectual architect. The change in rolling net income per share on GURU.Markets reflects the development dynamics, where -1.04 serves as the base parameter value, allowing analysts to assess the company's actual margin of safety.

Fate Therapeutics, Inc. (FATE) combines internal control over cell production with the outsourcing of clinical trials, creating a specific operational expenditure structure. The 12-month rolling earnings per share history reflects the final financial result distributed across the total volume of issuance, allowing investors to assess the business's actual margin of safety and the risks of capital freeze amid high borrowing costs.